Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | FPR2 | P25090 | 4/20 | 0.41 |
| ▸ | PROKR1 | Q8TCW9 | 4/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 3/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12099441 | 0.90 | EPHX2 (0.44) | FFAR1CHRM4KCNH2HRH3FPR2 | |
| SCHEMBL12100125 | 0.88 | FFAR1 (0.48) | FFAR1KCNH2HRH3 | |
| SCHEMBL12099606 | 0.86 | EPHX2 (0.41) | FFAR1KCNH2HRH3ACACB | |
| SCHEMBL12099589 | 0.86 | CHRM4 (0.46) | FFAR1CHRM4HRH3HRH1CCR3 | |
| SCHEMBL12099467 | 0.85 | FFAR1 (0.42) | FFAR1KCNH2HRH3FPR2PROKR1 | |
| SCHEMBL12099522 | 0.85 | ACACB (0.44) | FFAR1ACACB | |
| SCHEMBL12100012 | 0.84 | FFAR4 (0.39) | FFAR1KCNH2HRH3ACACB | |
| SCHEMBL12099739 | 0.84 | EPHX2 (0.45) | FFAR1KCNH2FPR2PROKR1HRH1 | |
| SCHEMBL12099685 | 0.81 | EPHX2 (0.42) | FFAR1CHRM4KCNH2HRH3FPR2 | |
| SCHEMBL12099684 | 0.81 | ACACB (0.42) | FFAR1KCNH2HRH3FPR2PROKR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN1A, SCN2B | FFAR1 793/4885CHRM4 1127/4885KCNH2 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.